To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Avista in $350m pharma exit
The firm has sold biopharmaceutical testing company BioReliance, which it acquired in 2007 for $210m.
